Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.
Acute lymphoblastic leukemia
Capizzi interim maintenance
High dose methotrexate
Methotrexate toxicity
Serum methotrexate levels
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
09
08
2019
accepted:
27
12
2019
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
11
7
2020
Statut:
ppublish
Résumé
Methotrexate (MTX) forms the backbone of maintenance cycles in childhood acute lymphoblastic leukemia (ALL) chemotherapy, including interim maintenance. There is sufficient published data describing toxicities of high dose MTX (HD-MTX), but toxicities with escalating doses of MTX (Capizzi regimen) is not well documented. Capizzi regimen is thought to be relatively safe; we contend that even low escalating doses of MTX have significant toxicities. Our study intends to characterise such events with Capizzi MTX in comparison to that seen with HD-MTX. The retrospective study was conducted at a tertiary care centre of North India. We looked for the presence of six main toxicities: febrile neutropenia, thrombocytopenia, mucositis, hepatic toxicity, renal toxicity and skin toxicity from the clinical records of children with newly diagnosed acute lymphoblastic leukemia and lymphoma (intermediate and high risk disease), treated at our centre from November 2013 to July 2018. Intermediate risk ALL (IR-ALL) received Capizzi MTX, whereas high risk ALL (HR-ALL/T-NHL), received HD-MTX. Both these regimens do not use L-asparaginase. A total of 237 cycles of Capizzi escalating MTX and 151 cycles of HD-MTX (B cell: 3 gm/m
Identifiants
pubmed: 32647424
doi: 10.1007/s12288-019-01245-z
pii: 1245
pmc: PMC7326748
doi:
Types de publication
Journal Article
Langues
eng
Pagination
498-504Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2020.
Déclaration de conflit d'intérêts
Conflict of interestAll authors have declare that they have no conflict of interest.
Références
J Clin Oncol. 2014 Mar 20;32(9):949-59
pubmed: 24550419
Eur J Cancer Care (Engl). 2008 May;17(3):306-11
pubmed: 18419635
Cancer. 1985 Sep 15;56(6):1356-60
pubmed: 3875390
Oncotarget. 2017 Jun 6;8(23):37761-37772
pubmed: 28525903
Indian Pediatr. 2015 May;52(5):385-9
pubmed: 26061923
J Pediatr. 2009 May;154(5):688-93
pubmed: 19159907
Oncologist. 2016 Dec;21(12):1471-1482
pubmed: 27496039
Int J Pediatr Adolesc Med. 2016 Dec;3(4):162-168
pubmed: 30805487
N Engl J Med. 1983 Mar 3;308(9):477-84
pubmed: 6571946
Br J Haematol. 2014 Aug;166(3):410-20
pubmed: 24712521
Gen Pharmacol. 1999 Feb;32(2):215-8
pubmed: 10188622
J Clin Oncol. 1998 May;16(5):1712-22
pubmed: 9586883
Pharmacogenet Genomics. 2014 Aug;24(8):387-96
pubmed: 25007187
Cancer Chemother Pharmacol. 2016 Nov;78(5):1093-1096
pubmed: 27659182
Pediatr Blood Cancer. 2018 Dec;65(12):e27241
pubmed: 29768710
Cancer Chemother Pharmacol. 1989;24(4):243-5
pubmed: 2546688
Indian J Med Paediatr Oncol. 2016 Apr-Jun;37(2):85-9
pubmed: 27168705
J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8
pubmed: 16462575
Pediatr Hematol Oncol. 2019 Sep;36(6):344-351
pubmed: 31514565
Drug Intell Clin Pharm. 1982 Nov;16(11):839-42
pubmed: 6959800
J Clin Oncol. 1994 Aug;12(8):1667-72
pubmed: 8040679
Leukemia. 2001 Jan;15(1):74-9
pubmed: 11243403
Clin Biochem. 1999 Oct;32(7):519-36
pubmed: 10614715
Anticancer Drugs. 2013 Feb;24(2):189-97
pubmed: 23187460
Leuk Lymphoma. 2012 Jun;53(6):1096-104
pubmed: 22074251